Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection

David P Serota; Harold A Franch; Emily J Cartwright

doi:10.1093/ofid/ofy189

Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection

Open Forum Infect Dis. 2018 Jul 30;5(8):ofy189. doi: 10.1093/ofid/ofy189. eCollection 2018 Aug.

Authors

David P Serota¹, Harold A Franch^{2

3}, Emily J Cartwright^{1

2}

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia.
² Atlanta VA Medical Center, Veterans Health Administration, Atlanta, Georgia.
³ Division of Renal Medicine, Department of Medicine, Emory University, Atlanta, Georgia.

Abstract

HIV treatment with tenofovir alafenamide fumarate (TAF) has decreased renal toxicity compared with tenofovir disoproxil fumarate in clinical trials. We report the case of a patient with HIV/HCV coinfection who was started on a TAF-based HIV regimen and developed acute kidney injury that worsened with the addition of sofosbuvir-ledipasvir.

Keywords: HIV infection; acute kidney injury; hepatitis C; tenofovir alafenamide.

Abstract

Grants and funding